Feb 6 (Reuters) - Bristol-Myers Squibb Co BMY.N:
Q4 ADJUSTED EPS $1.67 VERSUS IBES ESTIMATE $1.46
Q4 REVENUE $12.34 BILLION VERSUS IBES ESTIMATE $11.57 BILLION
OUTLOOK 2025 ADJUSTED EPS $6.55 TO $6.85 VERSUS IBES ESTIMATE $6.92
EXPANDS STRATEGIC PRODUCTIVITY INITIATIVE TO DELIVER ABOUT $2 BILLION IN ADDITIONAL COST SAVINGS BY2027 END
OUTLOOK 2025 REVENUES OF ABOUT $45.5 BILLION VERSUS IBES ESTIMATE $47.36 BILLION
((Reuters.Briefs@thomsonreuters.com;;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。